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Stroke is the third leading cause of death and the primary cause of morbidity in the
United States, thus posing an enormous burden on the healthcare system. The factors
that determine the risk of an individual toward precipitation of an ischemic event possess a
strong circadian component as does the ischemic event itself. This predictability provided a
window of opportunity toward the development of chronopharmaceuticals which provided
much better clinical outcomes. Experiments from our lab showed for the first time
that neuronal susceptibility to ischemic events follows a circadian pattern; hippocampal
neurons being most susceptible to an ischemic insult occurring during peak activity in a
rodent model of global cerebral ischemia. We also demonstrated that the SCN2.2 cells
(like their in vivo counterpart) are resistant to excitotoxicity by glutamate and that this was
dependent on activation of ERK signaling. We are currently working on elucidating the
complete neuroprotective pathway that provides a barricade against glutamate toxicity in
the SCN2.2 cells. Our future experiments will be engaged in hijacking the neuroprotective
mechanism in the SCN2.2 cells and applying it to glutamate-susceptible entities in an
effort to prevent their death in the presence of excitotoxicity. Despite the advancement
in chronopharmaceuticals, optimal clinical outcome with minimal adverse events are
difficult to come by at an affordable price. Superior treatment options require a better
understanding of molecular mechanisms that define the disease, including the role of the
circadian clock.
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CIRCADIAN RHYTHMICITY
Perhaps the most ubiquitous and persistent environmental factor
present throughout the evolution of modern species is the revo-
lution of the earth about its own axis, creating a 24 h solar day.
The consequent recurrent pattern of light and darkness endows a
sense of time to organisms that live on this planet. The impor-
tance of this sense of time is accentuated by an internal clock
that functions on a 24 h scale, inherent in the genetic framework
of living organisms ranging from cyanobacteria (Johnson et al.,
1996) to human mammals (Herzog and Tosini, 2001). An inter-
nal, molecular program drives circadian oscillations within the
organism that manifest at the molecular, biochemical, physiolog-
ical and behavioral levels (Mazzoccoli et al., 2012). Importantly,
these oscillations allow anticipatory responses to changes in the
environment and promote survival.
The term “circadian” comes from the Latin “circa,” meaning
“around” and “diem,” meaning “day.” Circadian events recur dur-
ing the subjective day or the lighted portion of the 24 h period and
the subjective night or the dark part of the 24 h period allowing
physiological synchrony with the light/dark environment (Reddy
and O’Neill, 2010). The circadian clock has been demonstrated
in almost all living organisms (Johnson et al., 1996; Herzog and
Tosini, 2001; Mazzoccoli et al., 2012). The two defining character-
istics of the circadian timing system are perseverance of oscillation
under constant environmental conditions, which define these
rhythms as self-sustained and endogenously generated, and the
ability to adapt to environmental change, particularly to changes
in the environmental light/dark cycle (Tischkau and Gillette,
2005). Endogenous rhythms can be entrained to the outside
world by several external cues of which light is the most widely
studied and probably the best understood. Such external cues
are called as “zeitgebers” or “time-givers” (Tischkau et al., 1999).
Although other “zeitgebers” such as seasonal changes and daily
temperature variations can also entrain internal rhythms to the
outside world, they are currently outside the purview of this arti-
cle and will not be discussed any further. Rhythms have been
studied in whole animals (Tischkau et al., 2000), individual tis-
sues (Tischkau et al., 2000), organs (Xu et al., 2010; Tischkau et al.,
2011; Wang et al., 2011) and cell culture models (Welsh et al.,
1995; Allen and Earnest, 2002). Perhaps the most obvious of all
circadian rhythms is the behavioral rest/activity cycle (Ibuka et al.,
1977; Mouret et al., 1978), which has been the subject of intense
study, providing a behavioral standard for investigation of rhyth-
micity. Circadian cycles are also expressed in physiology and gene
expression (Barnes et al., 2003; Karman and Tischkau, 2006).
Coherent circadian rhythms in mammals may be viewed as
an organismic network. In the complex system of mammals,
the master circadian pacemaker is the SCN (suprachiasmatic
nucleus), located in the hypothalamus, above the optic chiasm
from which it derives its name. Although individual neurons
within the SCN are independent oscillators, organismic rhythm
generation is considered an emergent property of the nucleus
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(Tischkau and Gillette, 2005). Nestled in the optic chiasm, and
connected to the external environment through a direct, monosy-
naptic connection from specialized retinal ganglion cells, the SCN
monitors environmental levels of illumination, which are inte-
grated and information based upon these data transmitted to the
rest of the organism through a variety of neuroendocrine mecha-
nisms (Moore, 1993; Hannibal, 2002; Fabbian et al., 2013). Thus,
the SCN harnesses and coordinates individual biological clocks
located in several different tissues and organs in the body and
thus is able to control multiple physiological processes and main-
tain their cyclical pattern in synchrony with the outside world.
So, what controls the master clock? The answer lies in a molecular
feedback loop consisting of the core group of clock genes (Lincoln
et al., 2003).
The core molecular clockworks consists of several major genes
including Per (Period), Tim (Timeless), Cry (Cryptochrome),
Clock (Circadian Locomotor Output Cycles Kaput) and Bmal1
(Brain Muscle ARNT-Like 1; ARNT = Aryl hydrocarbon
Receptor Nuclear Translocator) (Lincoln et al., 2003). Molecular
interactions between these genes govern the central time-keeping
mechanism in the suprachiasmatic nucleus neurons and help to
synchronize them in order to maintain the clock integrity (Siepka
et al., 2007). Typically, intracellular levels of Clock remain con-
stant throughout the 24 h period. BMAL1 expression is high
during the day and low at night. When present in sufficient lev-
els, BMAL1 heterodimerizes with CLOCK and together they bind
to E-box sequences in the promoter region of Cry (Cry1, 2) and
Per (Per1, 2, 3) genes. The BMAL1-CLOCK heterodimer also
turns off Bmal1 transcription. The results of BMAL1-CLOCK
activity are, therefore, reduction of Bmal1 transcript levels and
concomitant activation of Per and Cry at the beginning of the
day. Similar to BMAL1-CLOCK, Per and Cry form heterodimers
that enter the nucleus at the beginning of night. CRY disrupts
the CLOCK-BMAL1 interaction at E-box elements. As a result,
BMAL1 levels drop, thus reducing the amount of the BMAL1-
CLOCK heterodimer, thereby suppressing transcription of Per
and Cry, and allowing transcription of BMAL1. Regulation of
the BMAL1-CLOCK complex by ancillary feedback loops pro-
vides stability to the molecular oscillator. The nuclear receptors
ROR1α (Retinoid-related Orphan Receptor 1α) and Rev-erbα
provide positive and negative regulation of the BMAL1 promoter,
respectively. The interacting positive and negative feedback loops
of circadian genes ensures low levels of Per and Cry, and a high
level of Bmal1 at the beginning of a new circadian day (Siepka
et al., 2007). In Drosophila, the Tim gene interacts with Per to
act as a negative regulator of the CLOCK and the fly homolog of
BMAL1, CYCLE. (Bae et al., 1998). Disruption of any one of these
components results in a dysfunctional clock and an eventual state
of less than optimum physiology (Ohdo, 2010; Doi, 2012).
THE CIRCADIAN CLOCK AND DISEASE
Decades of research has time and again demonstrated the impor-
tance of the internal time-keeping mechanism in maintaining
optimum integrity of the organism as a whole. The SCN con-
trols several core physiological processes which include, but are
not limited to, heart rate (Morris et al., 2012), core body tem-
perature (Li et al., 2012), glucose metabolism (Li et al., 2012),
cortisol levels (involved in controlling blood pressure) (Clow
et al., 2010), sleep-wake cycle (Franken and Dijk, 2009) and hor-
mones of the reproductive cycle (Swaab et al., 1996). Surgical or
electrolytic lesioning of the suprachiasmatic nucleus results in
a state of complete arrhythmia in rodents (Mosko and Moore,
1979). Thus, the central molecular clock coordinates the activi-
ties of clocks residing in peripheral tissues and in this way entrain
several biological process to the outside world (Brown and Azzi,
2013). Alteration of the clock and/or expression or suppression
of one or more clock genes, cause deviation from homeosta-
sis in the physiology of an organism and is predictive of disease
(Mazzoccoli et al., 2012). Such altered patterns are quite typically
observed in the livers of animals subjected to a high fat diet (Shi
et al., 2013), or humans undergoing shiftwork (Berger andHobbs,
2006) and jetlagged animals (Filipski et al., 2004). Recent studies
have demonstrated a strong correlation between a disrupted clock
and an increased incidence of several diseases and disorders such
as obesity (Shi et al., 2013), metabolic syndrome (Xu et al., 2010),
diabetes (Wang et al., 2011), breast cancer (Haus and Smolensky,
2013), sleep disorders (Haus and Smolensky, 2013), depression
(Li et al., 2013) and certain neurological conditions (Jagannath
et al., 2013). In order to demonstrate the tremendous importance
of clock genes in physiology, we have incorporated a brief list of
clock gene malfunction, matched to the corresponding patholog-
ical state that its malfunction manifests, as summarized in Table 1
below. We are of course aware of the tremendous proportions of
literature available that barely even begins to describe the rami-
fications of circadian disruption in pathology of several diseases
and disorders. We are not providing a comprehensive list, but just
a brief glimpse of the role of clock gene malfunction in mediating,
maintaining or exacerbating pathology.
Excitingly, a picture is gradually emerging that progression
and fates of many diseases are tied to the health of the clock;
a healthy body contains a healthy clock. Disruption of clock
function may be an important contributor in disease. Several
studies demonstrate the importance of a healthy clock to car-
diovascular health. One study used transverse aortic constriction
to induce compensated heart and valve disease (characterized by
cardiac hypertrophy and hyperplasia) in mice (Martino et al.,
2007). This condition was exacerbated in mice subjected to a
lighting schedule that differed from their regular day-night pat-
tern. Cardiac clock gene profiling revealed a gross alteration
in the rhythmic gene expression. The pathological state of the




Clock-mutant Metabolic syndrome (Turek et al., 2005)
CLOCK and
BMAL1 disruption
Hypoinsulinaemia and diabetes (Marcheva et al.,
2010)
Cry-deficiency Hyperinsulinemia and tissue-specific insulin
resistance
(Barclay et al., 2013)
Per-deficiency Increased spontaneous and radiation-induced
tumor development (Lee et al., 2010)
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cardiac tissue was rescued after the rodents were reverted to their
regular day-night cycling (Martino et al., 2007). A similar study
demonstrated the importance of the biological clock in main-
taining normal physiology. Hamsters with the tau mutation have
severe cardiac and renal morbidities and a shortened lifespan
(Martino et al., 2008). This is because the tau mutation results
in a shorter period and therefore these animals cannot adapt to
the 24-hour cycle. However, when placed in a cycle that is normal
for this mutation i.e., the 22-h cycle, the hamsters display normal
cyclical behaviors and a normal cardio-renal phenotype charac-
teristic of a healthy animal (Martino et al., 2008). Other studies
have utilized clock gene knockout mice for demonstrating the
importance of a healthy circadian rhythm in maintaining normal
cardiovascular physiology. One such study conducted, involved
the induction of cardiovascular pathology in Bmal1 knockout
mice and Clock mutant mice by common carotid artery liga-
tion (Anea et al., 2009). Ligation of the common carotid artery
mimics the pathological course of cardiovascular diseases such
as atherosclerosis and hypertension that occurs in human beings.
This study showed that common carotid artery ligation triggers
a dramatic cardiac remodeling response that attempts to sal-
vage cardiac tissue from forming scar tissue and rescues optimal
function. However, in mice with a disrupted circadian physiol-
ogy (Bmal1 knockout and Clock mutant mice), common carotid
artery ligation prompts a less than optimum response, which
results in a worsening cardiovascular pathology as compared to
their wild-type counterparts (Anea et al., 2009). Whether clock
disruption is the cause or the outcome of the diseased condi-
tions remains largely unknown; but, partial restoration of clock
function appears to alleviate the symptoms of such diseases, slow
down the progression or improve the outcomes of treatments
(Sewlall et al., 2010; Hermida et al., 2013).
Considering that cardiovascular diseases rank first in terms
of long-term treatment and mortality, it is not surprising that
these conditions warrant the utmost urgency in determining ther-
apeutic strategies for reducing the tremendous burden on the
healthcare system. The cardiovascular system has long since been
known to harbor circadian components (Paschos and FitzGerald,
2010). It is common knowledge that certain aspects of the cardio-
vascular system vary with time of day, such as sympathetic tone,
vascular reactivity, heart rate and blood pressure (Paschos and
FitzGerald, 2010). Ramifications of these circadian events extend
to factors that govern the onset, maintenance and progression of
cardiovascular dysfunction including stroke (Uen et al., 2009).
Observational studies and a recent meta-analysis have shown that
stroke and cardiac arrest occur predominantly in the morning
(Hassler and Burnier, 2005; White, 2007; Patel et al., 2008; Uen
et al., 2009), thus demonstrating that just as the physiological
aspect of the cardiovascular system is governed by a circadian
overlord, so is its dysfunctional state governed by a time-of-day
variation.
CIRCADIAN RHYTHMS AND STROKE
Stroke is the third leading cause of death and the primary cause of
morbidity in the United States. Basic science and clinical research
have repeatedly revealed that stroke, among other cardiovascu-
lar events such as myocardial infarction, sudden cardiac death
and arrhythmias, has a propensity to precipitate at a particular
time-of-day; wherein these events are most likely to occur dur-
ing the hours of 6:00 a.m. and 12:00 p.m. (Hassler and Burnier,
2005; Manfredini et al., 2005; White, 2007; Patel et al., 2008;
Uen et al., 2009). Not only is the incidence of an ischemic
event (such as acute myocardial infarction) higher during the
morning hours, but the mortality resulting from such an event
was also higher during this time (Manfredini et al., 2004). A
retrospective clinical human study, demonstrated that myocar-
dial injury and decreased LV (Left Ventricular) function was
the worst when STEMI (ST-Elevation Myocardial Infarction)
occurred in the early morning hours and when reperfusion fol-
lowed 4 h later (Reiter et al., 2012). This timeline is reminiscent
of the sleep-wake transition period. A similar study assessed the
effect of time-of-day with respect to myocardial injury occur-
ring in STEMI patients undergoing PPCI (Primary Percutaneous
Coronary Intervention) (Fournier et al., 2012). When STEMI
occurred in the early morning hours (between 00:00 and 05:59)
infarct size was greater, with increased damage to myocardial
tissue and a higher mortality at 30-days. This study therefore con-
cluded that time-of-day should be factored in when assessing the
prognosis after STEMI (Fournier et al., 2012).
Primary evidence of this early morning susceptibility has been
linked to a variety of factors that are activated or inhibited during
this time, many of which possess a strong circadian component.
Although causative data to evaluate mechanisms underlying these
diurnal variations are lacking, circadian rhythms in activity, blood
pressure, platelet aggregatability, cortisol and catecholamines are
candidate factors (Bridges andWoods, 2001; Hassler and Burnier,
2005; White, 2007; Patel et al., 2008; Uen et al., 2009). These fac-
tors contribute to greater blood coagulability during the early
morning hours, rendering the subject more susceptible to the
adverse effects of ischemic events. Other factors that might also
contribute to a greater coagulable state are plasma cortisol, plasma
renin activity, angiotensin II, aldosterone, arterial stiffness, vas-
cular resistance, blood viscosity, (Hassler and Burnier, 2005) as
well as “increased reactive oxygen species formation by mononu-
clear cells, increased ubiquitin-proteasome activity (associated
with inflammation-induced plaque rupture) in atherosclerotic
lesions, greater common carotid artery intima-media thickness
values, physical exertion, emotional state (anger) and sexual activ-
ity” (Patel et al., 2008). Any one of the above mentioned factors or
a combination of some might trigger an ischemic event resulting
in a stroke.
Data collected over the past decade suggest a causative link
between hypertension, commonly referred to as a “silent killer”
and stroke (Dinsdale et al., 1978). Among all the factors that con-
tribute to a stroke, blood pressure is the one factor which has
displayed a very strong correlation to stroke incidence and clin-
ically is the most practical to measure and manipulate. Some
studies demonstrated that maintaining blood pressure within
normal limits during the peak susceptibility hours (early morn-
ing) can reduce adverse cardiovascular events, stroke in particular
(White, 2007; Patel et al., 2008). On the other hand, some other
researchers alleged that it was the night-time blood pressure
that predicated the risk of an individual toward a stroke (Uen
et al., 2009; Yano and Kario, 2012a,b). These studies have used
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a classification system for determining the population at high-
est risk for stroke. This system is based on the “dipping status”
of an individual. These studies classified subjects as “dippers”
(blood pressure dropped at night), “non-dippers” (blood pressure
did not drop at night) and “inverted dippers” or “risers” (blood
pressure was increased at night). These studies demonstrated that
the “non-dippers” and “risers” were more susceptible to ischemic
events and that controlling the rise of blood pressure at night
would produce a better outcome than that obtained by control-
ling the early morning surge. In either case, all studies provided
irrefutable evidence that ischemic events follow a certain circa-
dian pattern. Irrespective of the cause of the ischemic event, this
collective literature clearly showed that the factors contributing
to an ischemic event follow a circadian pattern that corresponds
with the actual event.
Neuronal susceptibility to death increases with age and sev-
eral factors come into play, which determine how an individual’s
body will react to a certain ischemic event: environmental fac-
tors such as diet, exercise, individual habits (drinking, smoking,
chewing tobacco, addiction to drugs), stress, presence of co-
morbidities (obesity, diabetes), family history, genetic tendencies
and of course, age. A vast amount of empirical evidence suggests
that with progression in age, several aspects of the physiology
become less efficient with time, and the time-keeping system is no
exception. Tested by time, classic circadian studies have demon-
strated that the aging process interferes with the time-keeping
system (Weitzman et al., 1982; Czeisler et al., 1999; Duffy and
Czeisler, 2002). Our findings clearly show that pathological con-
ditions are associated with deviation of the clockwork system
from its original, physiological state (Tischkau et al., 2007).
A more recent and sophisticated approach toward studying
factors that put certain individuals at a greater risk for a cer-
tain event than the general population, is the use of genetic
biomarkers. This approach is gaining rapid popularity due to the
availability of advanced instrumentation and the cardiovascular
field is no exception. Although blood pressure management pro-
vided a great therapeutic outcome in the treatment of several
cardiovascular diseases in the past, it was by no means without
several disadvantages. Blood pressure has a very strong circadian
component (Bridges and Woods, 2001) and that can act as a
double-edged sword; while it provides a good means for identi-
fying individuals at a high risk for adverse cardiovascular events
and can be practically manipulated, it is usually measured dur-
ing an office visit by the patient (White, 2007). Round-the-clock
portable measuring cuffs provided some resolution to that prob-
lem (White, 2007), but, it is rather impractical to ask a patient
to wake up every other hour to take an accurate reading of their
blood pressure and take their medication accordingly. Hence,
there is a tremendous need to find better treatment approaches
and the answer lies in first gaining a better understanding of the
disease itself.
DIURNAL VARIATION IN NEURONAL DAMAGE INCURRED BY
ISCHEMIC INSULT IN A RAT MODEL
Several physiological factors such as inherent increased coagula-
bility in the early morning or the presence of comorbidities such
as hypertension and cardiovascular diseases predispose subjects
to an ischemic event (Patel et al., 2008). However, none of the
studies thus far have ventured to determine whether an inher-
ent underlying susceptibility to neuronal damage at a particular
time of day would exacerbate the extent of damage caused by an
ischemic event as opposed to an identical event occurring at a
time of day when the inherent neuronal susceptibility to dam-
age was lower. In a clinical setting, it is difficult to establish such
a cause and effect relationship. Yet studies using animal models
to predict susceptibility and damage to ischemic insult are sparse.
In one study, rats were subjected to middle cerebral artery occlu-
sion at various times of the day (Tischkau et al., 2007). Rats were
most sensitive to the effects of ischemia at the beginning of their
active period and least susceptible at the beginning of their inac-
tive period (Tischkau et al., 2007). Infarct volume was more than
three times greater during the most sensitive time of day than it
was during the insensitive period. Based on this information, a rat
model was developed to evaluate the effect of time of day on the
extent of damage induced by an ischemic event in the hippocam-
pus; a region of the brain that is highly susceptible to stroke in
humans.
Rats were maintained in a 12-12 LD (light-dark) cycle, with
the day beginning at ZT0 (Zeitgeber time 0, defined as the time
of lights “on” at 7:00 a.m.) and ending at ZT12 (lights “off”
at 7:00 p.m.). The dark period spanned from ZT12 to ZT24/0.
Surgically induced cardiac arrest produced a global ischemia
that resulted in reproducible and consistent episodes of ischemic
events. A thoracotomy was performed under isoflurane anes-
thesia; the aortic root and pulmonary artery were clamped for
4min, under conditions of no ventilation resulting in cardiac
arrest and inhibition of total blood flow to the entire brain.
Animals were kept on heating pads during the entire proce-
dure to nullify the neuroprotective effects of hypothermia. The
study addressed 2 major questions: (1) Does time-of-day at which
ischemic insult occur affect the expression of biomarkers pre-
ceding cell death in the hippocampus? (2) Does an ischemic
insult cause a deviation in the expression pattern of clock
genes from that of the normal pattern of expression? The hip-
pocampus was the brain region under investigation because this
region is particularly susceptible to damage during the after-
math of a stroke. In order to assess the damage occurring after
an ischemic event, several cell death markers such as caspase
3, caspase 8 and caspase 9 were employed. Programmed cell
death, or apoptosis, is an evolutionarily conserved process that
plays a major role in development and in maintenance of tis-
sue homoeostasis (Cohen, 1993). Furthermore, apoptosis is a
common feature of many neurodegenerative disorders (Rubin
et al., 1994), including stroke (Choi, 1996). Thus, apoptosis is
an inherent part in health and disease. Apoptotic processes are
classified into 2 major pathways: 1) the intrinsic (or mitochon-
drial pathway, involving caspases 3 and 9 and 2) extrinsic (or
death receptor pathway, involving caspase 8 pathways (Debatin,
2004). Activated caspases 3, 8, and 9 have been used as reliable
markers for predicting cell death as an outcome in a vast array
of studies ranging from in vitro cell culture to in vivo animal
models, in different types of tissues such as cardiac tissue and
brain tissue and in varying operator hands in labs all over the
world.
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Animals were subjected to global ischemia by cardiac arrest at
ZT6, ZT14, and ZT20 and sacrificed 24 h later (Tischkau et al.,
2007). These time-points were chosen because ZT6 is a time-
point of peak rest period and ZT14 and ZT20 are time-points of
activity-onset and late activity periods respectively. ZT6 is analo-
gous to activity-onset in humans whereas ZT14 and ZT20 would
be periodsmuch later than the activity-onset time-point. This dif-
ference stems from the fact that while rodents are nocturnal (peak
activity during the dark period), humans are diurnal (peak activ-
ity during the light period). A significant elevation of caspase-3
mRNA was observed in ischemic hippocampi at ZT14 (early in
the active period). Also, although there was a small but signif-
icant increase in the protein levels at ZT6, a dramatic increase
in caspase-3 protein levels was evident when the ischemic insult
was initiated at ZT14. Similarly, although there was a significant
increase in caspase-8 mRNA at ZT6 (2.9 fold), the increase at
ZT14 was much greater (10.0 fold). However, the protein levels
were significantly elevated only with respect to the sham con-
trols; time-of-day did not seem to play a part in the extent of
elevation of caspase-8 protein levels. Caspase-9 transcript levels
were increased at ZT6 (3.3 fold) and ZT20 (3.3 fold); however,
the increase at ZT14 was much higher (8.3 fold). Following the
same trend, caspase-9 protein levels after ischemia were substan-
tially higher at ZT14 (15 fold) than at ZT20 (2.4 fold); there was
no change in the caspase-9 protein levels at ZT6. It is also impor-
tant to note here that the transcript and protein levels for caspases
3, 8 and 9 did not change in the sham controls with respect to
time of day. These results strongly suggest that damage occurring
in the aftermath of an ischemic insult initiated in the early night
(ZT14) is drastically greater than the damage occurring after an
insult initiated at a different time in the nocturnal cycle.
One of the popular theories explaining neuronal death is the
“calcium overload theory” (Lok and Martin, 2002). According
to this theory, an excitotoxic insult such as excessive glutamate
release, results in extensive depolarization of a neuron, which
prompts the N-methyl D-aspartate Receptors (NMDARs) to
open. These channels promote a massive calcium deluge into
the cell. Persistent activation of these channels causes a “cal-
cium overload” into the neuron which the cell cannot get rid off
fast enough. This causes over-activation of all calcium-dependent
processes, which provides conflicting information on what cell
process to activate, deactivate or maintain. Subsequently, unable
to keep up with the arrival of conflicting messages, the system
goes into over-drive and exhausts itself, killing the cell.
The physiological defense system against this calcium over-
load is executed by a family of calcium buffering proteins such
as calretinin, parvalbumin and calbindin. Several studies have
time and again demonstrated the importance of calbindin in
buffering the excess calcium entering a neuronal cell during an
ischemic excitotoxic insult. Calbindin overexpression protected
striatal neurons from the aftermath of transient focal cerebral
ischemia (Yenari et al., 2001). A couple of other studies have
also shown that calbindin-expressing neurons are better equipped
to survive ischemic and excitotoxic insults (Robier and Le Scao,
1991). Two other studies also clearly demonstrated the benefits
of short-term overexpression of calbindin in protecting neurons
from an excitotoxic insult in vitro and in vivo (Yenari et al.,
2001; Fan et al., 2007). Therefore, expression of calbindin, or lack
thereof might determine propensity toward exacerbated damage
in presence of an excitotoxic insult such as stroke. In the car-
diac arrest model, calbindin levels were significantly reduced at
all time-points, but the greatest reduction was observed at ZT14.
This taken together with the caspase data further strengthens the
idea that regions of the brain susceptible to excitotoxic insult
are inherently more susceptible at specific times-of-day. Inherent
neuronal susceptibility to this ischemic event follows a circadian
pattern.
To further elaborate on the circadian nature of inherent neu-
ronal susceptibility to ischemic damage, changes in the pattern of
expression of Clock genes were determined. The typical expres-
sion pattern is indicative of a healthy clock (Reddy and O’Neill,
2010). Any kind of deviation from the physiological expression
of these genes suggests a perturbation in the normal physiol-
ogy. Consistent with previous reports, in untreated controls, Clk
expression did not change with respect to time of day while Per1
and Cry1 were in-phase with each other (peaking during the early
morning and late night, with a trough during the later day and
early night). Bmal1 expression was out-of-phase with that of Per1
and Cry1. Animals were subjected to global ischemia at ZT6 and
hippocampi were collected at 0 (ZT6), 6 (ZT12), 12 (ZT18), 18
(ZT24), and 24 (ZT6, the next day) hours after surgery. The sham
controls followed the same expression pattern as the untreated
controls. The expression patterns of Bmal1 and Cry1 were unaf-
fected by global ischemia. Per1 levels on the other hand were
significantly affected by ischemia. Ischemia resulted in Per1 eleva-
tion at 6 h and 12 h after the ischemic insult when compared to the
sham controls. The Per1 levels at 18 h and 24 h after ischemia were
significantly lower than their sham-operated counterparts. Taken
together, these results suggest that ischemia resulted in a phase-
advance of Per1 expression. This study provided strong evidence
for the existence of inherent susceptibility to neuronal damage
that varies with time of day.
THE SCN AND RESISTANCE TO EXCITOTOXICITY
The previous study elaborately described the inherent suscep-
tibility of neurons to ischemia that changes with respect to
time-of-day, but made no attempt to explore mechanisms that
may underlie the susceptibility to ischemic damage. Glutamate
is the major excitatory neurotransmitter in the brain but its
release is tightly regulated by a complex array of biochemical
reactions (Westbrook, 1993). However, under several pathological
conditions, excessive glutamate release results in severe neu-
ronal obliteration (Michaelis, 1993). The hippocampus is highly
susceptible to glutamate-induced damage and several theories
suggest that glutamate may be a causative factor in the degenera-
tion caused by stroke and other neurodegenerative diseases (Coyle
and Puttfarcken, 1993). However, under physiological conditions
certain populations of neurons are naturally resistant to gluta-
mate insult; the SCN neurons are among those that are resistant.
Figure 1 depicts the typical ERK (Extracellular Regulated Kinase)
signaling in response to light in the SCN. Physiologically, light
activates retinal ganglion cells that project onto the SCN and
release glutamate (Kornhauser et al., 1996). Glutamate release
results in activation of glutamate receptors (GluR) that in turn
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FIGURE 1 | Light-induced ERK phosphorylation is required for
producing an appropriate response to the light stimulus.
activate ERK (by phosphorylation). Activated ERK is required for
several transcriptional and translational changes that are essen-
tial for turning the hands of the clock. Previous studies have
demonstrated that blocking ERK inhibits the response to light
(Butcher et al., 2003). This process of glutamate release occurs for
as long as light continues to activate the retinal ganglion cells. As
a result, the retino-recipient region of the SCN is subjected to a
continuous glutamate barrage. Unlike the hippocampal neurons,
SCN cells thrive in this seemingly “toxic” glutamate environ-
ment. Attempts to lesion the SCN using excitotoxins fail; the
SCN continues regular functioning even after glutamate treat-
ment. Histological evidence failed to demonstrate neuronal death
in the SCN neurons after ischemia or excitotoxin treatment.
MechanismsthatunderlieexcitotoxicresistanceinSCNneurons
were explored in the SCN2.2 cell line (Bottum et al., 2010).
The SCN2.2 cell line is derived and immortalized from the rat
SCN (Earnest et al., 1999). Previous studies have reliably and
reproduciblydemonstrated that this cell line adheres to the features
of theSCN invivo i.e., its clockproperties (AllenandEarnest,2002).
More importantly, theSCN2.2 cells are resistant toglutamate insult
(Bottum et al., 2010). However, mechanisms that underlie the
resistance of these peculiar neurons in the presence of glutamate
remain under investigated. This was of special interest because
these neurons are the major time-keepers in our brain i.e., they
belong to the SCN. The GT1-7 cell line, derived from the GnRH
(Gonadotropin Releasing Hormone) neurons from the mouse
hypothalamus (Liposits et al., 1991), was used as a control. GT1-7
cells are susceptible to 5mM glutamate whereas the SCN2.2 cells
thrive comfortably in 10mM of glutamate (Bottum et al., 2010).
While SCN2.2 cells survive up to 100 h in 10mM glutamate,
GT1-7 cells have reduced metabolic activity as early as 8 hours
and their live population starts declining by 40 h (Bottum et al.,
2010). The significance of the GT1-7 cell line is that it is derived
from neurons that lie in close proximity to the SCN in vivo,
but display neither the circadian properties nor the resistance to
glutamate, both of which are possessed by the SCN neurons.
The “resistance” of the SCN neurons was initially thought to be
due to inability of these neurons to respond to glutamate i.e., lack
of the NMDAR which is infamously notorious for its propensity
toward initiating and propagating neuronal damage under patho-
logical conditions (Frandsen and Schousboe, 1987). However,
several studies have shown that the SCN in vivo possesses func-
tional NMDARs. In order to entrain the various physiological and
behavioral rhythms to the environment, the endogenous clock
must be reset periodically and it does this primarily by using light
from the environment as a cue. Light reaches the SCN via a direct
retinal projection, the RHT (Retino-Hypothalamic Tract) (Mosko
and Moore, 1979; Moore, 1993). Light falling on the retina acti-
vates the optic nerve to carry photic information via a specific
subset of retinal ganglion cells in the RHT to the SCN (Ebling,
1996; Mintz et al., 1999). Optic nerve stimulation releases gluta-
mate onto the SCN (Liou et al., 1986). In hypothalamic slices, glu-
tamate and NMDA (N-methyl D-aspartate) mimic the effects of
light (Ding et al., 1994). NMDAR antagonists block these effects
(Colwell andMenaker, 1992; Colwell et al., 1992). These data pro-
vide conclusive evidence that NMDARs present on the SCN are
necessary and sufficient for SCN function. NMDAR subunit tran-
scripts and protein are expressed in SCN2.2 cells (Bottum et al.,
2010). However, the functionality of these receptors in the SCN2.2
cells remains undetermined as of now.
Evidence of gargantuan proportions demonstrates that MAPK
(Mitogen-Activated Protein Kinases) determine cell fate (among
a myriad of other functions that are outside the scope of this
review) in neurons and other cell systems (Park et al., 2008;
O’Sullivan et al., 2009; Zhong et al., 2009). There are 3 main
mammalian MAPK molecules, namely, ERK (de Lemos et al.,
2010), p38 (Han et al., 1995), and SAPK/JNK (Stress-Activated
Protein Kinase; Jun N-terminal Kinase) (Minden et al., 1994).
Although controversial, ERK has been largely demonstrated as
a pro-survival kinase whereas p38 and SAPK/JNK are more
involved in a cell death-mediating effect. Each of these kinases
at some point have been purported to play an opposite role in
determining cell fate. These ambiguities in outcomes are probably
due to different cell types, tissues, investigation systems (in vivo,
in vitro or ex vivo), different operators and a host of other factors.
The role of each of these kinases in the SCN2.2 cell line in the pres-
ence of an excitotoxic glutamate insult was explored. In each case,
the phosphorylated form of the kinase indicates its active state. In
our study (Karmarkar et al., 2011), we found that glutamate con-
sistently increased the phosphorylated (activated) ERK (p-ERK)
levels in SCN2.2 cells; there was no change in the GT1-7 cells.
At 48 h post glutamate treatment, p-ERK levels were significantly
lowered in GT1-7 cells but still elevated in the SCN2.2 sam-
ples. These data are consistent with a pro-survival role for ERK
signaling in the SCN2.2 cells. There was no change in the phos-
phorylated (activated) p38 (p-p38) levels in the glutamate-treated
SCN2.2 cells, but they were increased in the glutamate-treated
GT1-7 cells at 12 h post-glutamate treatment. At 48 h, the p-
p38 levels remained unchanged in the SCN2.2 samples and were
only slightly (but significantly) reduced in the glutamate-treated
GT1-7 cells. These data are consistent with a pro-death role
for p38 in the GT1-7 cells. The p-SAPK/JNK levels remained
unchanged with treatment in both the cell systems at 48 h of
treatment and for the entire short-term treatment in the GT1-7
cells. Previous literature suggests that although prolonged stress
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is often deleterious to a system, an acute and low-profile stress
can be neuroprotective as it alerts the system to activate signaling
mechanisms that prevent further damage to the system. This par-
ticular model for the role of SAPK/JNK fit well with the transient
SAPK/JNK activation in SCN2.2 cells in response to a glutamate
stressor. Thus, both ERK and SAPK/JNK are most likely responsi-
ble for inciting the neuroprotective signaling cascade in response
to the glutamate insult.
Pre-treatment of the SCN2.2 cells with an ERK inhibitor
(PD98059) prior to glutamate or NMDA treatment significantly
increased the susceptibility of SCN2.2 cells to excitotoxicity, as
assessed by the live-dead assay, metabolic activity assay, caspase-3
activity assay and cleaved (activated) caspase-3 immunocyto-
chemistry. This cell death was prevented by the presence of the
NMDAR blocker MK-801 (irrespective of whether glutamate or
NMDAwas used in the presence of the ERK inhibitor). These data
demonstrated that the glutamate-mediated toxicity (in the pres-
ence of the ERK inhibitor) is dependent on NMDAR signaling.
In summary, SCN2.2 cells, like their in vivo counterparts, are
resistant to glutamate toxicity. The conclusions from our stud-
ies led us to propose a hypothetical model which is summarized
in Figure 2 below. The SCN2.2 cells are damaged by glutamate if
ERK is inhibited simultaneously. This glutamate-mediated tox-
icity is dependent on NMDAR signaling. However, ERK is a
very “broad” kinase with myriad functions that vary with dif-
ferent systems under divergent conditions. Therefore, further
studies should focus on determining the upstream regulators of
ERK activation and narrowing down on the downstream effector
molecules that prevent SCN2.2 cells from dying. Once a neuro-
protective pathway has been established, the same pathway could
be hijacked in neurons that are susceptible to glutamate dam-
age and prevent their cell death in the presence of an excitotoxic
insult. Furthermore, it is not just what signaling pathway should
be hijacked but also what would be the appropriate time to initiate
it and for how long it should be maintained in an activated state.
The studies outlined here represent the first foray into under-
standing mechanisms that render certain neurons resistant to
hostile excitotoxic conditions that would obliterate most other
FIGURE 2 | ERK phosphorylation is essential for protecting the SCN2.2
cells from a glutamate insult.
neurons in the brain. The investigation of the role of circadian
properties in determining susceptibility or resistance to a cer-
tain cell fate is in its infancy. There is the need for tremendous
research to be performed to seek out molecular targets which one
day would result in successful therapies in the battle against the
aftermath of ischemic events such as stroke.
Emerging evidence puts forward another possibility that time-
keeping phenomenon inherent to the SCN is by itself a neuropro-
tective mechanism.Molecules such as melatonin and prokineticin
that are responsible for allowing the SCN to keep time might
themselves provide the SCN an inherent resistance to being “over-
worked” i.e., protect against stressful conditions such as excessive
glutamate. Melatonin is available over the counter as a remedy
for insomnia, for fighting jet-lag, as an anti-oxidant (free radi-
cal scavenger) and an anti-inflammatory agent      (Al-Omary, 2013).
Several studies have time and again demonstrated that melatonin
possesses neuroprotective properties in several neurodegenera-
tive disorders (Carpentieri et al., 2012). Similarly, prokineticin
serves as one of the chief output signals of the SCN (Li et al.,
2012). Prokineticin-mediated activation of its receptor results
in activation of G-coupled proteins which are in turn coupled
with activation of MAPK/Akt (Ngan and Tam, 2008). By virtue
of coupling of prokineticin to MAPK/Akt, prokineticin action
mediates a broad spectrum of biological actions such as differ-
entiation, proliferation and migration of target cells (Ngan and
Tam, 2008). It is only a matter of time until the right pharma-
ceutical formulation is designed to safely administer melatonin
and/or prokineticin and put their true potential to the test. Our
current studies have been limited to using the SCN2.2 immor-
talized cell line. The major advantage of using a cell line is that
several experiments can be performed simultaneously and are
easily reproduced several times. However, the major drawback of
this system is that it does not take into account the in vivo cyto-
architecture and the intricate “network” of neuronal interactions.
Subject to funding availability, we will continue to pursue simi-
lar studies, first in SCN slices, followed by whole animal studies
in vivo.
CHRONOPHARMACEUTICALS AND STROKE
It is now largely accepted that a single office blood pressure mea-
surement is not sufficient to determine whether an individual is
essentially at a high risk for the precipitation of an ischemic event
(Neutel and Smith, 1997). Therefore, the long-sustained practice
of simply combining different anti-hypertensives for achieving
better blood pressure management, no longer holds true. Portable
blood pressure measurement devices helped give a better basis
for sorting out those individuals who are at a high risk for an
ischemic event (Neutel and Smith, 1997). Data from more recent
studies have further strengthened the argument for incorporat-
ing ambulatory blood pressure monitoring as a part of standard
care. This is particularly applicable to subjects who are at a greater
risk of incidence of ischemic events. A recent article has described
in exquisite the detail, the urgent need for ambulatory blood
pressure management for the early diagnosis of asymptomatic,
hypertensive subjects and as a clinical “marker” for assessing ther-
apeutic outcome in patients already being treated for a myriad
of post-ischemic diseases (International Society for et al., 2013).
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This would be especially pertinent in patients with concomi-
tant disorders such as diabetes, chronic kidney disease, metabolic
syndrome and sleep disorders, as these conditions could poten-
tially adversely affect the therapeutic treatment of the ischemic
event. However, continuous therapeutic monitoring being cost-
prohibitive and repeated dosing at certain intervals being imprac-
tical provoked the need for a completely different treatment
strategy. This is where chronopharmaceuticals are helping make
headway into a practical therapeutic approach which produces
optimal clinical outcome with least possible adverse events and
is also financially affordable.
With the identification of the importance of circadian biol-
ogy in health and disease (Reddy and O’Neill, 2010), considerable
investments are ensuing to develop particular treatment regi-
mens that focus on the importance of chronobiology; time-of-day
is now being considered for its relevance to treatment efficacy
with reduction in adverse reactions. This means that round-
the-clock therapeutic clinical monitoring becomes essential in
order to tailor the regimen according to the need of each indi-
vidual subject. Although feasible in theory, executing this type
of treatment strategy in practice is cost-prohibitive. The cur-
rent efforts to overcome this hurdle lie in the development of
chronopharmaceuticals.
Chronopharmaceuticals are drugs that are given at a par-
ticular time of day, predicated by the expected onset of an
event at a particular time (Sewlall et al., 2010). One review
article elegantly summarized several cardiovascular medications
(beta-blockers, calcium channel blockers, nitrates and aspirin)
that have been tested for their potential as a chronopharma-
ceutical for optimal efficacy (Bridges and Woods, 2001). Some
of these drugs are already approved by the FDA and some
are under investigation for better pharmacokinetics (includ-
ing, but not limited to extended release formulations) (Sewlall
et al., 2010). Several clinical trials are already in place to test
chronopharmaceuticals in the prevention or mitigation of sev-
eral diseases such as asthma, allergic rhinitis, arthritis, cancer
and cardiovascular disorders including those precipitated by
ischemic events (Sewlall et al., 2010). Past clinical trials involv-
ing timed dosing of individual anti-hypertensives have yielded
mixed conclusions (Bridges andWoods, 2001). The current trend
is toward exploring the efficacy of newer formulation types
using drugs that are already approved by the FDA. Clinical
trials using novel drug delivery systems have provided promis-
ing results; some of the most notable ones are the COER
(Controlled-Onset, Extended-Release) −24 verapamil clinical
trial, CODAS (Chronotherapeutic Oral Drug Absorption System)
verapamil clinical trial, diltiazem (Cardizem XL) clinical trial
and the CONVINCE (Controlled Onset Verapamil INvestigation
of Cardiovascular Endpoints) clinical trial (White and LaRocca,
2002).
Although there are some controversies over whether control-
ling increased blood pressure at night or inhibiting the early-
morning surge would produce better results, the undeniable con-
clusion attained at the end of these trials was that circadian events
could be potentially harnessed for more effective treatment regi-
mens resulting in optimal management of the disease with least
possible adverse events. Thus, understanding the physiological
factors that increase susceptibility to an ischemic event and more
importantly, predicting when these factors are more likely to
trigger such an event would provide superior management of a
disease.
CONCLUSIONS
Cardiovascular diseases rank the highest in terms of mortality.
The risk for development of these diseases is based on a whole
host of factors which essentially determine the state of coagu-
lability of an individual; greater the coagulation factors present,
the greater the incidence for precipitation of an ischemic event
(White and LaRocca, 2002). The most practical to manipulate
among these factors is blood pressure because it is non-invasive
and can be performed by the subject outside the clinic (Pickering
et al., 1985). Although portable blood pressure monitoring has
become easy to report, the simple combination of a variety of
anti-hypertensives has failed to produce the optimal results that
it had promised.
Blood pressure has a strong circadian rhythm wherein it peaks
upon onset of activity and dips during the period of least activity
(Bridges and Woods, 2001). Previous studies aimed at reducing
the early morning surge in order to obtain better control of blood
pressure and thereby potentially reduce the incidence of ischemic
events in these individuals (Patel et al., 2008). This treatment
approach, however, did not produce an effective blood pressure
control in a significant number of individuals which ended up
being subjected to the ischemic events anyway. This led to a newer
hypothesis that it was the “dipping status” of the night-time blood
pressure that would be more effective in determining the risk of
an individual toward an ischemic event i.e., subjects in which the
blood pressure dipped at night (“dippers”) were at a lower risk of
an ischemic episode in contrast to individuals whose blood pres-
sures did not dip (“non-dippers”) or actually increased (“risers”)
(White, 2007). This finding then became the new “gold-standard”
for treatment of blood pressure; to cause the blood pressure to
dip at night in the “non-dippers” and “risers” in order to achieve
blood pressure control and thereby reduce the risk of an ischemic
event in these populations.
This led to the development of chronopharmaceuticals that
have in several clinical trials proven to be more efficacious in
blood pressure management than the previous long-sustained
practices (Bridges and Woods, 2001; White and LaRocca, 2002;
Sewlall et al., 2010). However, majority of these clinical trials
are based on empirical findings and as such lack the fundamen-
tal principles on which even better treatment approaches can be
built. This is where basic science research is essential in order
to determine the molecular mechanisms underlying the patho-
logical onset, maintenance and progression of the disease. Only
by clearly defining the disease will it become possible to target
molecular culprits and achieve the best possible treatment regi-
men for subjects at an affordable price and simultaneously reduce
the burden on the healthcare system.
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